Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned

MedGenMed Medscape General Medicine

Volumn 10, Issue 5, 2008, Pages

  Atwood IV, Kimball C ^a,e   Woockner, Elizabeth ^b   Baratz, Robert S ^c,f,g   Sampson, Wallace I ^d,h  

^a NEWTON WELLESLEY HOSPITAL   (United States)

^b CIRCARE (Citizens for Responsible Care and Research)   (United States)

^c South Shore Health Center Inc   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g National Council Against Health Fraud Inc

^h SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; EDETATE CALCIUM DISODIUM; EDETATE DISODIUM; EDETIC ACID; GLYCERYL TRINITRATE; HYDROGEN PEROXIDE; LAETRILE; MINERAL; PLACEBO; PYRIDOXINE; RETINOL; RIBOFLAVIN; VITAMIN; ZINC; CHELATING AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; AMBULATORY CARE; ANEMIA; ANGINA PECTORIS; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CEREBROVASCULAR DISEASE; CHELATION THERAPY; CHILL; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DERMATITIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FACE INJURY; FAINTNESS; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSURIA; HEALTH PRACTITIONER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HEMATURIA; HOMEOPATHY; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOTENSION; INFORMED CONSENT; INJECTION SITE BURNING; INSTITUTIONAL REVIEW; KETONURIA; KIDNEY FAILURE; KIDNEY INJURY; LACRIMATION; LEAD POISONING; LETHARGY; LEUKOPENIA; LOW DRUG DOSE; MALAISE; MALPRACTICE; MOUTH LESION; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEGLIGENCE; NEOPLASM; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OSTEOLYSIS; OZONE THERAPY; PERIPHERAL VASCULAR DISEASE; POLITICS; PRACTICE GUIDELINE; PROTEINURIA; RESEARCH ETHICS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SNEEZING; THIRST; THROMBOPHLEBITIS; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URINARY URGENCY; VOMITING; ALTERNATIVE MEDICINE; FINANCIAL MANAGEMENT; HEALTH CARE ORGANIZATION; INTRAVENOUS DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; UNITED STATES;

CHELATING AGENTS; CHELATION THERAPY; CLINICAL TRIALS, PHASE III AS TOPIC; COMPLEMENTARY THERAPIES; CORONARY ARTERY DISEASE; EDETIC ACID; ETHICS, RESEARCH; HUMANS; INJECTIONS, INTRAVENOUS; NATIONAL INSTITUTES OF HEALTH (U.S.); RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 44349086029     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (326)

1. National Institutes of Health. EDTA Chelation Therapy for Coronary Artery Disease. RFA: AT-01-004. Citizens for Responsible Care and Research (CIRCARE). Available at: http://www.circare.org/tact/ rfa_AT-01-004.pdf Accessed March 6, 2008.
2. National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health. NIH launches large clinical trial on EDTA Chelation Therapy for Coronary Artery Disease [press release]. Bethesda, Md: NCCAM; August 7, 2002. Available at: http://nccam.nih.gov/chelation/ pressrelease.htm Accessed March 6, 2008.
3. National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health. Questions and answers: the NIH trial of EDTA Chelation Therapy for Coronary Artery Disease. October 24, 2007. Available at: http://nccam.nih.gov/chelation/q-and-a.htm Accessed March 6, 2008.
4. Lamas GA (principal investigator). Clinical Trial Protocol for grant application RFA: AT-01-004, Trial to Assess Chelation Therapy. August 29, 2001. Obtained under the Freedom of Information Act. Citizens for Responsible Care and Research (CIRCARE). Available at: http://www.circare.org/tact/tactprotocol_20010829.pdf Accessed March 6, 2008.
5. Lamas GA (principal investigator). Trial to Assess Chelation Therapy (TACT). Protocol. Version 2. May 30, 2003. Obtained under the Freedom of Information Act. Citizens for Responsible Care and Research (CIRCARE). Available at: http://www.circare.org/tact/tactprotocolv2_20030530.pdf; http://www.circare.org/tact/tactprotocolv2b_20030530.pdf Accessed March 6, 2008
6. Lamas GA. Consent form, Trial to Assess Chelation Therapy (TACT). Version 2. June 30, 2003. Cit7izens for Responsible Care and Research (CIRCARE). Available at: http://www. circa re.org/tact/ tactconsentform_20030613. pdf Accessed March 6, 2008.
7. Citizens for Responsible Care and Research (CIRCARE). Trial to Assess Chelation Therapy (TACT): Index of Tables. Available at: http://www.circare.org/tact/tact_tableindex.htm Accessed April 26, 2008.
8. American College for Advancement in Medicine (ACAM). Find an ACAM physician. Available at: http://www.acam.org/dr_search/ index.php?q=USA&search=Search&field=country&submitted=1 Accessed March 6, 2008.
9. Soffer A. Chelation therapy for arteriosclerosis. JAMA. 1975;233:1206-1207. Abstract
10. Soffer A. Chihuahuas and Laetrile, chelation therapy, and honey from Boulder, Colo. Arch Intern Med. 1976;176:865-866.
11. Soffer A. Chelation clinics: an abuse of the physician's freedom of choice. Chest. 1984;86:157-158. Abstract
12. Edetate disodium injection USP (Endrate) [package insert]. (After DESI 1974-07-16). North Chicago, III: Abbott Laboratories. Available at: http://www.circare.org/foia2/endrate_ppi19740716.pdf Accessed March 6, 2008.
13. Centers for Disease Control. Deaths associated with hypocalcemia from chelation therapy - Texas, Pennsylvania, and Oregon, 2003-2005. MMWR. 2006;55:204-207. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm5508a3.htm?s-cid=mm5508a3_e Accessed March 6, 2008.
14. In the State Court of Dekalb County State of Georgia. Mabel Alexander et al vs Progressive Medical Group et al. Civil Action File No. 03A-12798-2. Available at: http://www.quackwatch.org/14Legal/pmg.html Accessed March 6, 2008.
15. In the Matter of the License of Kenneth W. O'Neal, M.D. Before the Disciplinary Panel of the Texas Medical Board. October 28, 2005. Available at: http://www.casewatch.org/board/med/oneal/oneal.shtml Accessed March 6, 2008.
16. National Council Against Health Fraud. Chelation doctor to pay $2.15 million in damages. NCAHF News. March/April 1996;19(2). Available at: http://www.ncahf.org/nl/1996/3-4.html Accessed March 6, 2008.
17. Schulte F, Bergal J. They wanted to look better, feel better. Sun-Sentinel. December 11, 1999. Available at: http:/web.archive.org/web/ 20001204221900/ http://www.sun-sentinel.com/news/daily/detail/ 0,1136,26000000000106678,00.html Accessed March 6, 2008.
18. United States v. An Article of Drug*** Diso-tate, et al. United States District Court for the Eastern Division of Louisiana. No. 75-1790. Vincent A. Kleinfeld, Alan H. Kaplan, and Stephen A. Weitzman. Federal Food, Drug, and Cosmetic Act Judicial Record 1975-1977 (FDLI, Washington, DC 1979). September 28, 1976. Citizens for Responsible Care and Research (CIRCARE). Available at: http://www.circare.org/tact/17-1790_19760928.pdf Accessed March 6, 2008.
19. Elkins D. "Chelation therapy" suit is one of med-mal, not products liability. Virginia Mad Law Rep. November 2005:4.
20. State of Wisconsin Before the Medical Examining Board in the Matter of the Disciplinary Proceedings Against Eleazar Mira Kadile, M.D. Complaint. December 3, 2001. Available at: http://quackwatch.org/11Ind/ kadile.html Accessed March 6, 2008.
21. Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication - a double-blind, placebo-controlled study. J Intern Med. 1992;231:261-267. Abstract
22. Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg. 1991;162:122-125. Abstract
23. Guldager B, Brixen KT, Jorgensen SJ, et al. Effects of intravenous EDTA treatment on serum parathyroid hormone (1-84) and biochemical markers of bone turnover. Dan Med Bull. 1993;40:627-630. Abstract
24. Jorgensen SJ, Guldager B, Jelnes R. EDTA treatment of arteriosclerosis. Bias or manipulation? [in Danish]. Ugeskr Laeger. 1992; 154:1645-1646. Abstract
25. Van Rij AM, Solomon C, Packer SG, Hopkins WG. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation. 1994;90:1194-1199. Abstract
26. Hopf R, Gleubner M, Babej-Dolle R, Kaltenbach M. Wirksamkeit von Chelat bei Patienten mit koronarer Herzkrankheit. Z Kardiol. 1997;76(suppl2):31.
27. Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA. 2002;287:481-486. Abstract
28. Anderson TJ, Hubacek J, Wyse DG, Knudtson ML. Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. J Am Coll Cardiol. 2003;41:420-425. Abstract
29. Lamas GA, Ackermann A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? Am Heart J. 2000;140:4-5.
30. ACAM News Release/Position Statement. American College for the Advancement in Medicine defends use of FDA approved therapy. August 29, 2005. redOrbit Web site. Available at: http://www.redorbit.com/news/ health/223696/american_college_for_the_advancement_in_medicine_ defends_use_of/ Accessed April 25, 2008.
31. Calcium disodium versenate-(edetate calcium disodium injection USP) [package insert]. Northridge, Calif: 3M Pharmaceuticals, Lake Forest, III: Hospira, Inc; July 2004. Available at: http://www.circare.org/foia2/ 3M_ca2na_versenate.pdf Accessed March 6, 2008.
32. Clarke NE, Clarke CN, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci. 1956;232:654-666. Abstract
33. Rozema TC. The protocol for the safe and effective administration of EDTA and other chelating agents for vascular disease, degenerative disease, and metal toxicity. J Adv Med. 1997;10:5-100.
34. Trowbridge JP. Historical perspectives on the development of chelation therapies. 1998. Available at: http://www.healthchoicesnow.com/docs/ CHELATIONHISTORYRTF1.doc Accessed March 6, 2008.
35. Cranton EM. A new theoretical mechanism of action of chelation therapy. Updated October 2006. Available at: http://www.drcranton.com/chelation/ theoreticalmech.htm Accessed March 6, 2008.
36. ACAM to create national chelation therapy credentialing program [press release). Laguna Hills, Calif: American College for Advancement in Medicine; January 19, 2006. Available at: http://web.archive.org/web/ 20060206040838/acam.org/press_release01_20.html Accessed March 6, 2008.
37. Herald Staff Report. Bradenton center wins study honor. Bradenton Herald. September 2, 2006. Available at: http://nl.newsbank.com/ nl-search/we/Archives?p_multi=BHI&p_product=BH&p_theme= realcities2&p_action=search&p_maxdocs=200&s site=bradenton&s_trackval=BH&s_dispstring= ("Bradenton%20center%20study%20honor")%20AND%20date(09/01/ 2006%20to%2009/03/2006)&p_field_date-O=YMD_date&p_params_date-O= date:B,E&p_text_date-O=O9/01/2006%20to%2009/03/2006) &p_field_advanced-0=&p_text_advanced-0= ("Bradenton%20center%20wins%20study%20honor")&xcal_ numdocs=20&p_perpage=10&p_sort=_rank-:D&xcal_ranksort= 4&xcal_useweights=yes Accessed April 25, 2008.
38. ClinicalTrials.gov. Trial to Assess Chelation Therapy (TACT). March 20, 2007. Available at: http://clinicaltrials.gov/ct/show/ NCT00044213?order=1 Accessed March 6, 2008.
39. Meeting Roster, National Center for Complementary and Alternative Medicine Special Emphasis Panel, National Center for Complementary and Alternative Medicine, ZAT1 K (02). January 4, 2002. Citizens or Responsible Care and Research (CIRCARE). Available at: http://www.circare.org/tact/nccamsepZAT1K02_20020104.pdf Accessed March 6, 2008.
40. Beecher HK. Ethics and clinical research. N Engl J Med. 1966;274:1354-1360.
41. Cardiovascular disease: is the government doing more harm than good? EDTA Chelation Therapy. Hearing before the Committee on Government Reform, House of Representatives, One Hundred Sixth Congress, first session. March 10, 1999. Serial No. 106-33. Available at: http://frwebgate.access.gpo.gov/cgi-bin/ getdoc.cgi?dbname=106_house_hearings&docid=f.59973.pdf Accessed March 6, 2008.
42. What is ACAM? A message from ACAM President Ted Rozema, MD. May 2000. Available at: http://web.archive.org/web/20000511115741/www.acam.org/ newsletter.htm Accessed March 6, 2008.
43. Celebration of Health Association. Curriculum Vitae, 2007. L. Terry Chappell, MD. Available at: http://www.healthcelebration.com/AboutCOHA/ AboutOurStaff/CurriculumVitaeChappell/tabid/84/Default.aspx Accessed March 6, 2008.
44. Paynter B. Miracle in a bottle. The Pitch. November 25, 2004. Available at: http://www.pitch.com/issues/2004-11-25/news/feature_full.html Accessed March 6, 2008.
45. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-146.
46. Miller PB, Weijer C. Rehabilitating equipoise. Kennedy Inst Ethics J. 2003;13:93-118.
47. Nash RA. Metals in medicine. Altern Ther Health Med. 2005;11:18-25.
48. National Center for Complementary and Alternative Medicine (NCCAM). List of Canadian study sites for chelation therapy study. Available at: http://nccam.nih.gov/chelation/studysitecan.htm Accessed March 7, 2008.
49. Lamas GA, Hussein SJ. EDTA chelation therapy meets evidence-based medicine. Br J Cardiol. 2006;13:5-6.
50. Clarke NE Sr, Clarke NE Jr, Mosher RE. Treatment of occlusive vascular disease with disodium ethylene diamine tetraacetic acid (EDTA). Am J Med Sci, 1960;239:732-744.
51. Meltzer LE, Ural ME, Kitchell JR. The treatment of coronary heart disease with disodium EDTA. In: Seven, MJ, ed. Metal Binding in Medicine. Philadelphia: Lippincott; 1960:43-47.
52. Lamar CP. Chelation therapy of occlusive arteriosclerosis in diabetic patients. Angiology. 1964;15:379-394. Available at: http://www.detoxamin.com/studies/study16/index.html Accessed March 6, 2008.
53. Lamar CP. Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatr Soc. 1966;14:272-294.
54. Kitchell JR, Palmon F, Aytan N, Meltzer LE. The treatment of coronary artery disease with disodium EDTA: a reappraisal. Am J Cardiol. 1963;11:501-506.
55. Soffer A. Chelation therapy for cardiovascular disease. In: Soffer A, Spencer H, Rubin M, et al, eds. Chelation Therapy. Springfield, III: Charles C. Thomas; 1964:15-33.
56. Staver S. $1-million libel suit a scary experience for MD-witness. Am Med News. June 13, 1980.
57. Dayton M. The case for intravenous EDTA chelation therapy. 1995, 1999, 2006. International College of Integrative Medicine. Available at: http://icimed.com/books_by_members.php Accessed March 6, 2008.
58. Rhea S. Chelation and the heart, Courier-Post Online. November 28, 2004. Reprinted on ACAM. Available at: http://web.archive.org/web/ 20050305115833/http://www.acam.org/media.htm Accessed April 25, 2008.
59. Joseph Witek, quoted in Schulte F and Bergal J. Controversial therapy lures problem doctors. Sun-Sentinel. December 13, 1999. Available at: http://web.archive.org/web/20010203213300/ http://www.sun-sentinel.com/ news/daily/detail/0,1136,26000000000107361,00.html Accessed March 6, 2008.
60. Before the Board of Medical Examiners of the State of North Carolina. In Re: Theodore Carl Rozema, MD. Findings of Fact. October 26, 1978. Available at: http://www.bioethicswatch.org/pd/rozema_19781026.pdf Accessed March 6, 2008.
61. Florida Department of Health, Practitioner profile. Available at: http://ww2.doh.state.fl.us/irm00profiling/ print_report.asp?Licld=1887&ProfNBR=1901&printer=TRUE Accessed April 27, 2008.
62. United States of America v. H. Ray Evers. Information for corruptly endeavoring to interfere with administration of internal revenue laws and intimidating and impeding officers of the Internal Revenue Service. CR No. 76-326, October 20, 1976. United States District Court Eastern District of Louisiana. Available at: http://www.circare.org/foia2/ evers_76-326_19761020.pdf Accessed March 6, 2008.
63. Herbert V. Testimony. Hearing Before the Subcommittee on Health and Long-Term Care of the Select Committee on Aging, House of Representatives. Ninety-Eighth Congress, Second Session. May 31, 1984. Comm. Pub. No. 98-463: 96-98.
64. Cranton EM, Frackelton JP. Current status of EDTA chelation therapy in occlusive arterial disease. Im Cranton EM, ed. Textbook of Chelation Therapy. 2nd ed. Updated and copyright 2001 by Elmer M. Cranton, MD. Available at: http://www.drcranton.com/chelation/emcjpf.htm Accessed March 6, 2008.
65. Spence JD. Letter to Jerome J. Papke, Program Officer DHEW, Social Security Administration Bureau of Health Insurance re: Meadowbrook Hospital, Belle Chasse, LA. December 29, 1975. Available at: http://www.circare.org/foia2/spence_wrtnrpt_19751229.pdf Accessed March 6, 2008.
66. Spence JD. Letter to W. Sherwood Lawrence, Medical Officer, California State Department of Health Food and Drug Section. July 9, 1976. Available at: http://www.circare.org/foia2/spence_lawrence_19760709.pdf Accessed March 6, 2008.
67. Common and statutory laws affecting practitioners: criminal charges. In: Laws and Regulations Governing Practitioners Who Offer Unconventional Cancer Treatments. Washington, DC: US Government Printing Office, U.S. Congress, Office of Technology Assessment, Unconventional Cancer Treatments, OTA-H-405 1990:220-221. Available at: http://www.princeton.edu/~ota/disk2/1990/9044_n.html Accessed April 25, 2008.
68. Johns Hopkins Bloomberg School of Public Health. Faculty Page of Alfred Sommer. July 17, 2006. Available at: http://faculty.jhsph.edu/ ?F=Alfred&L=Sommer Accessed March 6, 2008.
69. Barrett S. Be wary of the National Health Federation. From: Barrett S. "health freedom" crusaders. In: Barrett S, Jarvis WT, eds. The Health Robbers: a Close Look at Quackery in America. Buffalo, NY: Prometheus Books; 1993:397-411. Available at: http://www.quackwatch.org/ 04ConsumerEducation/Nonrecorg/nhf.html Accessed March 6, 2008.
70. Barrett S. Some notes on Robert Bradford and his Committee for Freedom of Choice in Medicine. Quackwatch. Revised February 2005. Available at: http://www.quackwatch.org/04ConsumerEducation/Nonrecorg/cfcm.html Accessed March 6, 2008.
71. Wilson B. The rise and fall of Laetrile. Quackwatch. Revised 2004. Available at: http://www.quackwatch.org/01QuackeryRelatedTopics/Cancer/ laetrile.html Accessed March 6, 2008.
72. Questionable methods of cancer management: the Committee for Freedom of Choice in Medicine, Inc. CA Cancer J Clin. 1993;43:117-123. Available at: http://caonline.amcancersoc.org/cgi/reprint/43/2/117 Accessed March 6, 2008.
73. Young JH. Laetrile in historical perspective. In: Young JH, ed. American Health Quackery. Princeton: Princeton University Press; 1992:205-255.
74. Barrett S. Former Laetrile peddler disciplined again. Quackwatch. February 2005. Available at: http://www.quackwatch.org/11Ind/ privitera.html Accessed March 6, 2008.
75. Young JH. Laetrile in historical perspective. In: Young JH, ed. American Health Quackery. Princeton: Princeton University Press; 1992:232.
76. US Supreme Court. United States v. Rutherford, 442 U.S. 544 (1979). Certiorari to the United States Court of Appeals for the Tenth Circuit. No. 78-605. Available at: http://wyomcases.courts.state.wy,us/ applications/oscn/deliverdocument.asp? id=430959&hits=12557+9998+8667+6648+5689+3452+2342+625+#t* Accessed March 6, 2008.
77. Supreme Court of the United States. The United States of America, et al., Petitioners v. Glen L. Rutherford, et al., Respondents. No. 78-605. October Term, 1978. April 5, 1979. Brief of Amicus Curiae American Academy of Medical Preventics in Support of Respondents Dennis S. Avery, 350 Cedar Street, San Diego, California 92101, Telephone: (714) 239-0391 ,Jerry W. Kane, 1800 Central Federal Tower, 225 Broadway, San Diego, California 92101, Telephone: (714) 238-1328 ,Attorneys for Amicus Curiae, American Academy of Medical Preventics.
78. Montgomery MR. Advances in medical fraud: chelation therapy replaces Laetrile. J Florida Med Assoc. 1986;73:681-685.
79. Gordon GF. American Academy of Medical Preventics. An Open Letter to Those Persons Interested in Chelation Therapy. Undated. Available at: http://www.circare.org/tact/aamp_openletter.pdf Accessed March 6, 2008.
80. Before the Board of Medical Examiners of the State of North Carolina In Re: Theodore Carl Rozema MD. Submission of Memorandum on Chelation Therapy. December 10, 1984. Available at: http://www.bioethicswatch.org/ pd/rozemamemorandum_19841210.pdf Accessed March 6, 2008.
81. American College for Advancement in Medicine (ACAM). Vision/mission. Available at: http://web.archive.org/web/20070201234303/ http://www.acam.org/vision.htm Accessed March 6, 2008.
82. American College for Advancement in Medicine (ACAM). J Adv Med. Available at: http://web.archive.org/web/20010110031300/www.acam.org/ Journal.htm Accessed April 25, 2008.
83. American College for Advancement in Medicine (ACAM). ACAM's Journal. Available at: http://web.archive.org/web/20010831160724/www.acam.org/ acamjournal.php Accessed March 6, 2008.
84. American Board of Chelation Therapy (ABCMT). About us. Available at: http://www.abcmt.org/ Accessed April 25, 2008.
85. International College of Integrative Medicine. Available at: http://icimed.com/index.php Accessed March 6, 2008.
86. American Association for Health Freedom. History. Available at: http://www.healthfreedom.net/index.php?option=com_content&task= view&id=15<emid=44 Accessed March 6, 2008.
87. American College for Advancement in Medicine (ACAM). Industry directory. Our premier partners. Available at: http://www.acamnet.org/site/ c.ItJWJ4MPIwE/b.2073037/k.C638/industry_Directory.htm Accessed March 7, 2008.
88. Detoxamin studies. Chelation therapy studies, Available at: http://www.detoxamin.com/chelationstudies.html Accessed March 6, 2008.
89. Titles and abstracts of published papers. McDonagh Medical Center. Available at: http://www.mcdonaghmed.com/abstracts.htm Accessed March 6, 2008.
90. Olszewer E, Carter JP. EDTA chelation therapy: a retrospective study of 2,870 patients. J Adv Med. 1989;2:197-211.
91. Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses. 1988;27:41-49. Available at: http://www.detoxamin.com/studies/study5/index.html Accessed 4/26/08.
92. Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc. 1990;82:173-177. Available at: http://www.detoxamin.com/studies/study2/ index.html Accessed March 6, 2008.
93. Spence JD. Statement to the Assembly Health Committee of the California Legislature re: SB 1474 and 1475, 1976. Available at: http://www.circare.org/foia2/spence_statementSB1474_1976.pdf Accessed March 6, 2008.
94. Carter JP. Racketeering in Medicine: the Suppression of Alternatives. Norfolk, Va: Hampton Roads Publishing; 1993.
95. Chappell LT, Stahl JP. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med. 1993;6:139-160. Available at: http://www.detoxamin.com/studies/study6/ index.html Accessed March 6, 2008.
96. Chappell LT, Stahl JP, Evans R. EDTA chelation treatment for vascular disease: a meta-analysis using unpublished data. J Adv Med. 1994;7:131-142. Available at: http://www.detoxamin.com/studies/study22/ index.html Accessed March 6, 2008.
97. Supreme Court of Missouri. State Board of Registration for the Healing Arts, Appellant v. Edward W. McDonagh, D.O., Respondent. SC85275. Handdown Date: December 23, 2003. Available at: http://www.courts.mo.gov/ courts/pubopinions.nsf/ccd96539c3fbl3ce8625661f004bc7da/ 1bd33b63fa48b5b/86256e4c006c1484?OpenDocument&Highlight=0,McDonagh Accessed March 7, 2008.
98. Missouri Division of Professional Registration. Licensee search detail: McDonagh, Edward W. Available at: http://pr.mo.gov/ licensee-search-detail.asp?passkey=1126298 Accessed March 6, 2008.
99. Canon S, Bavley A. Dubious cures dispensed to a vulnerable people. Kansas City Star. October 23, 1996. Available at: http://web.archive.org/ web/20040423112057/http://www.kcstar.com/plain/stories/main20.htm Accessed March 6, 2008.
100. ACAM to create national chelation therapy credentialing program1 [press release]. Laguna Hills, Calif: American College for Advancement in Medicine (ACAM); January 19, 2006. Available at: http://web.archive.org/ web/20060206040838/acam.org/press-release01_20.html Accessed March 6, 2008.
101. Autism Research Institute. Vaccinations and heavy metals. 2006. Available at: https://www.autismwebsite.com/ari/vaccine/vaccine.htm Accessed March 6, 2008.
102. American Board of Clinical Metal Toxicology. ABCMT standard of care for increased body burden of toxic metals. July 1, 2004. Available at: http://web.archive.org/web/20060517072757/http://www.abct.info/ 2005-01-11-ABCMT-StandardOfCare1.doc Accessed April 25, 2008.
103. Casdorph HR, Walker M. Toxic Metal Syndrome: How Metal Poisonings Can Affect Your Brain. New York: Penguin Group (USA); 1995. Available at: http://books.google.com/books?id=7GJEveEcurMC&pg=RA1-PA388&lpg= RA1-PA388&dq=casdorph+hr&source=web&ots=_2dnYdptn-&sig= 87NyrrzujAlFivu7_H8u5IXQEoM#PRA1-PR13,M1 Accessed March 6, 2008.
104. American Board of Clinical Metal Toxicology. A message from our chairman. 2004. Available at: http://web.archive.org/web/20041011172723/ abct.info/about/chairman.html Accessed March 6, 2008.
105. Cranton EM, Frackelton JP. Scientific rationale for EDTA chelation therapy: mechanism of action. In: Cranton EM, ed. A Textbook on EDTA Chelation Therapy. 2nd ed. Charlottesville, Va: Hampton Roads Publishing; 2001. Available at: http://www.drcranton.com/chelation/ freeradical.htm Accessed March 6, 2008.
106. Cranton E. Bypassing Bypass Surgery: Chelation Therapy: A Non-Surgical Treatment for Reversing Arteriosclerosis, Improving Blocked Circulation, and Slowing the Aging Process. Charlottesville, Va: Hampton Roads Publishing; 2001.
107. Kane K. Drug error, not chelation therapy, killed boy, expert says. Pittsburgh Post-Gazette. January 18, 2006. Available at: http://www.post-gazette.com/pg/06018/639721.stm Accessed March 6, 2008.
108. Commonwealth of Pennsylvania Bureau of Professional and Occupational Affairs vs. Roy Eugene Kerry, MD, Respondent. September 8, 2006. Available at: http://www.circare.org/pd/ kerry_ordertoshowcause_20060908.pdf Accessed March 6, 2008.
109. Before the Board of Naturopathic Examiners. State of Oregon. In the matter of Donald D. McBride, Jr., N.D. Agency Case No. NO5-11-13. Settlement Agreement and Consent Order. June 19, 2006. Available at: http://www.circare.org/pd/mcbride_orders_20060510.pdf Accessed March 6, 2008.
110. Oregon Board of Naturopathic Examiners. 850-060-0225 Naturopathic Formulary Compendium. Updated June 11, 2007. Available at: http://www.oregon.gov/OBNE/rules/850-060-0225.pdf Accessed March 6, 2008.
111. Oregon Board of Naturopathic Examiners. Continuing education course information. December 10, 2003. Available at: http://web.archive.org/web/ 20031212163628/http://www.obne.state.or.us/conted.htm Accessed March 6, 2008.
112. Centers for Medicare & Medicaid Services (CMS). Medicare coverage database. National Coverage Determination for Chelation Therapy for Treatment of Atherosclerosis (20.21). Available at: http://www.cms.hhs.gov/mcd/viewncd.asp?ncd_id=20.21&ncd_version=1 &basket=ncd%3A20%2E21%3A1%3AChelation+Therapy+for+Treatment+of+ Atherosclerosis Accessed March 6, 2008.
113. CIGNA Government Services. Progressive corrective action - chelation therapy. November 24, 2004. Available at: http://www.cignagovernmentservices.com/partb/pubs/news/2004/1104/ cope1692.html Accessed March 6, 2008.
114. American Board of Chelation Therapy. Constitution and by-laws. Adopted March 1982. Revised November 1982, April 1983, January 1984, April 1984, November 1987, November 1994. Article III: Definition of Chelation Therapy.
115. Nash RA. Cover letter to all State Medical Boards. July 1, 2004. Available at: http://web.archive.org/web/20060517072703/www.abct.info/ 005-01-11-ABCMT-Letter-July1-2004.doc Accessed March 6, 2008.
116. Center for the Healing Arts, PC. Directory and services. Available at: http://www.bestbusinessinstitute.org/82/ ?form_44.userid=28&form_44.replyids=1&form_271.userid= 28&form_271.replyids=1 Accessed March 6, 2008.
117. National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health. List of study sites for chelation therapy study. Available at: http://nccam.nih.gov/chelation/studysite.htm Accessed March 6, 2008.
118. Barrett S. Regulatory actions against Robban Sica, MD. Revised February 2005. Quackwatch. Available at: http://www.quackwatch.org/11Ind/ sica.html Accessed March 6, 2008.
119. Casewatch. Court dismisses attempt to block disciplinary action against Robban Sica, MD. October 30, 2004. Available at: http://www.casewatch.org/board/med/sica/deter.shtml Accessed March 6, 2008.
120. Missouri Code of State Regulations. Division 2150 - State Board of Registration for the Healing Arts Chapter 2 - Licensing of Physicians and Surgeons 20 CSR 2150-2.165 Chelation of No Medical or Osteopathic Value. Available at: http://www.sos.mo.gov/adrules/csr/current/20csr/ 20c2150-2.pdf Accessed March 6, 2008.
121. State policies, rules, law, and regulations on EDTA chelation therapy. Citizens for Responsible Care and Research (CIRCARE). Available at: http://www.circare.org/tact/state_policies.htm Accessed March 7, 2008.
122. Position statement. Tennessee Board of Medical Examiners. Alternative medicine or procedures without evidence of scientifically proven benefit that are effective and low risk. Adopted by the Board of Medical Examiners on this the 1st day of March, 2005. Available at: http://health.state.tn.us/Downloads/g4015060.pdf Accessed March 7, 2008.
123. State of Tennessee Department of Health. In the matter of: Russell Wayne Hunt, M.D., Respondent. Tennessee License No. 27007. Old Hickory, Tennessee. Before the Board of Medical Examiners. Docket no. 17.18-095746A. September 19, 2007. P. 2: Findings of fact. Available at: http://health.state.tn.us/licensure/displaypdf.asp?profcode= 1606&licen=27007&thedate=9/19/2007 Accessed March 7, 2008.
124. Scott PJ. Chelation therapy for degenerative vascular disease. N Z Med J. 1982;95:538-539. Abstract
125. Chelation therapy: a second look. Harvard Health Left. 1984;IX:1-3.
126. Carver JR, Samuels F. Sham therapy in coronary artery disease and atherosclerosis. Practical Cardiol. 1988;14:81-86.
127. Diagnostic and Therapeutic Technology Assessment (DATTA): chelation therapy. JAMA. 1983;250:672.
128. Top 10 Health Frauds. FDA Consumer. October 1989. Available at: http://www.findarticies.com/p/articles/mi_m1370/is_n8_v23/ai_8057613/ print Accessed March 6, 2008.
129. Green S. Chelation therapy: unproven claims and unsound theories. Quackwatch. Available at: http://www.quackwatch.org/ 01QuackeryRelatedTopics/chelation.html Accessed March 6, 2008.
130. The Great Lakes Association of Clinical Medicine. Institutional Review Board. 1999. Available at: http://web.archive.org/web/19990218064546/ www.arxc.com/glacm/irb.htm Accessed March 6, 2008.
131. List of studies approved by the GLCCM IRB and enrolling subjects in March 2000 when FDA suspended the IRB's authority. Citizens for Responsible Care and Research (CIRCARE). Available at: http://www.circare.org/foia2/glccmstudies.pdf Accessed March 6, 2008.
132. Citizens for Responsible Care and Research (CIRCARE). Great Lakes College of Clinical Medicine IRB Document Index. Available at: http://www.circare.org/foia2/docs.htm Accessed March 6, 2008.
133. Chappell LT. Letter of approval by the Great Lakes Association of Clinical Medicine Institutional Review Board to H. Heimlich M.D. for Induced Malaria study. May 27, 1994. Citizens for Responsible Care and Research (CIRCARE). Available at: http://www.circare.org/foia2/ giccm_hh19940527.pdf Accessed March 6, 2008.
134. Citizens for Responsible Care and Research (CIRCARE). Malariotherapy for HIV (Henry Heimlich M.D.) Available at: http://www.circare.org/ malariotherapy.htm Accessed March 6, 2008.
135. FDA Form 483 Issued to Paula R. Bickle, Ph.D. and Cascade Consultants Research Foundation. September 8, 1999. Available at: http://www.circare.org/foia2/483_bickle.pdf Accessed March 6, 2008.
136. Quackwatch. A critical look at "Dr." Paula Bickle. Revised May 13, 2004. Available at: http://www.quackwatch.org/11Ind/bickle.html Accessed March 6, 2008.
137. Audrey M. Snow v. Roy C. Page, Jane Reeb, and Ariadne Medical Group. Case No. 03CV00474. United States District Court Southern District of Alabama. Complaint. June 25, 2003. Available at: http:/twww.circare.org/ foia2/cv-03-2238.pdf Accessed March 6, 2008.
138. United States of America v. George Kindness and Amscot Medical Labs Inc. Case No. 03CR20433. United States District Court. Western District of Tennessee, Western Division. Indictment. November 19, 2003. Available at: http://www.circare.org/foia2/03_20433BV.pdf Accessed March 6, 2008.
139. United States of America v. George Kindness and Amscot Medical Labs Inc. Case No. 03CR20433. Plea Agreement. United States District Court. Western District of Tennessee, Western Division. July 6, 2005. Available at: http://www.circare.org/lex/03cr2G433_20050706.pdf Accessed March 6, 2008.
140. FDA Report of Establishment Inspection of GLCCM IRB by Hugh M. McClure III, 11/16-18, 22-24, 12/01/99. Available at: http://www.circare.org/ foia2/glccm_fdaeir19991201.pdf Accessed March 6, 2008.
141. Warning letter from Steven A. Masiello, Director, Office of Compliance and Biologies Quality, Center for Biologics Evaluation and Research, FDA, to L. Terry Chappell, M. D., Secretary, Great Lakes College of Clinical Medicine IRB. March 9, 2000. Available at: http://www.circare.org/foia2/fda_glccm20000309.pdf Accessed April 25, 2008.
142. American College for Advancement in Medicine. Sample protocol. Title of study: chelation therapy for arteriosclerotic disease. Informed consent, disclosure and acknowledgement form. Updated 1993. Available at: http://www.circare.org/tact/acamirb_sampleprotocol.pdf Accessed April 25, 2008.
143. Letter from Barbara Grunewald, Executive Director, Great Lakes College of Clinical Medicine, to Patricia Holobaugh, Division of Inspections and Surveillance, FDA. February 7, 2001. Available at: http://www.bioethicswatch.org/foia/giccm_fda20010207.pdf Accessed March 6, 2008.
144. Letter from L. Terry Chappell, M.D., Secretary, Great Lakes College of Clinical Medicine IRB, to Patricia Holobaugh, Division of Inspections and Surveillance, FDA. July 17, 2001. Available at: http://www.circare.org/foia2/giccm_fda20010717.pdf Accessed April 27, 2008.
145. Letter from Ralph Miranda, MD, Chairman, ACAM IRB, to "Investigator". November 17, 2001. Available at: http://www.circare.org/tact/acam_irbdisbanded20011127.pdf Accessed March 6, 2008.
146. Celebration of Health Association. Institutional Review Board activities (IRB). 2007. Available at: http://healthcelebration.com/MoreInformation/ IRBActivities/tabid/94/Default.aspx Accessed March 7, 2008.
147. Sampson W. The pharmacology of chelation therapy. Sci Rev Alternative Med. 1997;1:23-25. Available at: http://www.sram.org/0101/chelation.html Accessed March 6, 2008.
148. Green S, Sampson W. EDTA chelation therapy for atherosclerosis and degenerative diseases: implausibility and paradoxical oxidant effects. Sci Rev Alternative Med. 2002;6:17-22. Available at: http://www.sram.org/ 0601/chelation.html Accessed March 6, 2008.
149. Green S, Mazur A, Shorr E. Mechanisms of catalytic oxidation of adrenalin by ferritin iron. J Biol Chem. 1956;220:237-255.
150. Herbert V, Shaw S, Jayatilleke E. Vitamin C-driven free radical generation from iron. J Nutr. 1996;126(suppl):1213S-1220S. Erratum in: J Nutr. 1996;126:1902; J Nutr. 1996;126:1746.
151. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 2002;105:2107-2111.
152. American College for Advancement in Medicine. Consumer information about chelation therapy. Available at: http://web.archive.org/web/ 19961023062125/www.acam.org/cict.html Accessed March 6, 2008.
153. Hancke C. Letter to the editor. J Adv Med. 1994;7:108-109.
154. Godfrey ME, Frackleton JP, Chappell LT. Chelation therapy for intermittent claudication. N Z Med J. 1994;107:495.
155. Godfrey ME, Chappell LT. Chelation therapy for intermittent claudication - a reappraisal. N Z Med J. 1996;109:83.
156. Chappell LT, Miranda R, Rubin M, Carter JP, Trowbridge J. Chelation therapy. Circulation. 1995;92:1350-1352.
157. Schachter MB. Chelation therapy. Circulation. 1995;91:2291-2292.
158. Chappell LT, Wilson J, Ernst E. Chelation therapy for vascular disease. Response. Circulation. 1999;99:164-167.
159. Cranton EM. Chelation critics publish deceptive data. Mt. Ranier Clinic. Copyright 2007. Available at: http://www.drcranton.com/chelation/ chelationcritics.htm Accessed March 6, 2008.
160. Cranton EM. A summary of EDTA chelation clinical research: all good! Mt. Ranier Clinic. Copyright 2001. Available at: http://www.drcranton.com/ chelation/allgood.htm Accessed March 6, 2008.
161. Cranton EM. AMA publishes junk science in attempt to discredit chelation. Mt. Ranier Clinic. Copyright 2005. Available at: http://www.drcranton.com/sham.htm Accessed March 6, 2008.
162. Whitaker J. Memorandum to the Medical Board of California. December 14, 1994.
163. United States of America Federal Trade Commission. In the matter of American College for Advancement in Medicine, a corporation. Complaint. 1998. Available at: http://www.ftc.gov/os/1998/12/9623147cmp.htm Accessed March 6, 2008.
164. American College for Advancement in Medicine. Position paper on EDTA chelation therapy. Available at: http://web.archive.org/web/ 20030605082948/http://www.acam.org/chelationtherapyinformation.php or http://www.healthy.net/asp/templates/Article.asp?Id=262 Accessed March 6, 2008.
165. Ernst E. Chelation therapy for peripheral arterial occlusive disease: a systematic review. Circulation. 1997;96:1031-1033.
166. Ernst E. Chelation therapy for coronary heart disease: an overview of all clinical investigations. Am Heart J. 2000;140:139-141.
167. Complementary and Alternative Medicine in Government-Funded Health Programs. Hearing before the Committee on Government Reform, House of Representatives. One Hundred Sixth Congress, First Session. February 24, 1999. Serial No. 106-4. Available at: http://frwebgate.access.gpo.gov/ cgi-bin/getdoc.cgi?dbname=106_house_hearings&docid=f:56145.wais Accessed March 6, 2008.
168. American Association for Health Freedom, Access to Medical Treatment Act. June 8, 2005. Available at: http://www.apma.net/AMTA/AMTAtext.asp Accessed March 6, 2008.
169. Meeting summary of the National Heart, Lung, and Blood Advisory Council. February 10, 2000. Available at: http://www.nhlbi.nih.gov/meetings/ nhibac/feb00min.htm Accessed March 7, 2008.
170. Schaefer EA. Commerce Business Daily Issue of January 21, 2000 PSA#2520. Chelation therapy of angina pectoris SOL NIH-NHLBI-HC-00-05 POC. Available at: http://www.fbodaily.com/cbd/archive/2000/01(January)/ 21-Jan-2000/Asolo10.htm Accessed March 7, 2008.
171. Minutes of the Third Meeting - May 8-9, 2000. National Advisory Council for Complementary and Alternative Medicine (NACCAM). Available at: http://nccam.nih.gov/about/advisory/naccam/minutes/2000may.htm#p7 Accessed March 7, 2008.
172. Atwood KC. The ongoing problem with the National Center for Complementary and Alternative Medicine. Skeptical Inquirer. 2003;27:23-29. Available at: http://www.csicop.org/si/2003-09/ alternative-medicine.html Accessed March 7, 2008.
173. American Association for Health Freedom. History. Available at: http://www.healthfreedom.net/index.php?option=com_content&task= view&id=15<emid=44 Accessed March 7, 2008.
174. McDonagh EW, Rudolph CJ, Cheraskin E. The effect of EDTA chelation therapy plus supportive multivitamin-trace mineral supplementation upon renal function: a study in serum creatinine. J Holistic Mad. 1982;4:146-151. Available at: http://www.detoxamin.com/studies/study41/ index.html Accessed March 7, 2008.
175. Rudolph CJ, McDonagh EW, Wussow DG. The effect of intravenous disodium ethylenediaminetetraacetic acid (EDTA) upon bone density levels. In: Cranton EM, ed. A Textbook on Chelation Therapy. Charlottesville, Va: Hampton Roads Publishing; 2001:259-264.
176. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Available at: http://www.wma.net/e/policy/b3.htm Accessed March 7, 2008.
177. US Food and Drug Administration. Code of Federal Regulations. Title 21, part 312, section 312.21. Phases of an Investigation (21CFR312,21). Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.afm?FR=312.21 Accessed March 7, 2008.
178. National Center for Complementary and Alternative Medicine (NCCAM). Clinical considerations for all CAM interventions. "...this document will apply to all NCCAM clinical trial grant applications beginning January 1, 2003." Available at: http://nccam.nih.gov/research/ policies/clinical-considerations.htm#4 Accessed March 7, 2008.
179. National Center for Complementary and Alternative Medicine (NCCAM). Centers for Research on Complementary and Alternative Medicine (CRC) Program. FY 2003 Research Priorities. A priority to elucidate mechanisms of action and conduct small, well-developed phase I and II trials. December 2, 2002. Available at: http:/tweb.archive.org/web/ 20021215053952/http://nccam.nihov/research/priorities/index.htm#2 Accessed March 7, 2008.
180. National Center for Complementary and Alternative Medicine (NCCAM). FY 2003 research priorities. Cardiovascular diseases. December 2, 2002. Available at: http://web.archive.org/web/20021215053952/ http://nccam.nih.gov/research/priorities/index.htm#5 Accessed March 7, 2008.
181. Straus SE, Chesney MA. In defense of NCCAM. Science. 2006;313:303-304.
182. Marcus DM, Grollman AP. Review for NCCAM is overdue. Science. 2006;313:301-302.
183. Center for Scientific Review. National Institutes of Health, Review meeting procedures. Revised February 8, 2008:10-11. Available at: http://cms.csr.nih.gov/ResourcesforApplicants/ PolicyProcedureReview+Guidelines/Guidelines+for+Review+of+Specific+ Applications/Guidelines+For+Study+Section+Reviewers+and+Chairs/ Review+Meeting+Procedures.htm Accessed April 25, 2008.
184. National Center for Complementary and Alternative Medicine (NCCAM). National Advisory Council for Complementary and Alternative Medicine. Minutes of the Twenty-Sixth Meeting. February 2, 2007. Available at: http://nccam.nih.gov/about/advisory/naccam/minutes/2007febmin.pdf Accessed March 7, 2008.
185. The Center for the Improvement of Human Functioning International. Available at: http://brightspot.org/index.shtml Accessed March 7, 2008.
186. The Center for the Improvement of Human Functioning International. Gift of health store. Books: Colloidal Silver: The Natural Antibiotic Alternative by Zane Baranowski, CN. Available at: http://web.archive.org/ web/20060630105323/brightspot.org/Merchant2/ merchant.mvc?Screen=PROD&Product_Code=BCol&Category_Code= bks&Store_Code=GOH Accessed March 7, 2008.
187. The Center for the Improvement of Human Functioning International. Becoming a patient/co-learner. Available at: http://brightspot.org/ patient/index.shtml Accessed March 7, 2008.
188. The Center for the Improvement of Human Functioning International. Sample test results. Available at: http://biocenterlab.org/tests/hhb10/ btosample.pdf Accessed March 7, 2008.
189. Discovery Institute. A scientific dissent from Darwinism. Available at: http://www.discovery.org/articleFiles/PDFs/100ScientistsAd.pdf Accessed March 7, 2008.
190. In the Matter of Thaddeus J. Murawski, as Executive Secretary of the State Board for Professional Medical Conduct of the State of New York, Petitioner. Michael B. Schachter, Respondent Supreme Court of New York, Special Term, Albany County. 95 Misc. 2d 249; 406 N.Y.S.2d 968; 1978 N.Y. Misc. LEXIS 2410.
191. Cancer: Schachter Center for Complementary Medicine. Available at: http://www.mbschachter.com/cancer.htm Archived prior to August 2003 but available at: http://web.archive.org/web/20020220102502/ http://mbschachter.com/cancer.him Accessed April 25, 2008.
192. Schachter Center for Complementary Medicine. Success stories. Available at: http://schachtercenter.com/success_stories.htm Accessed March 7, 2008.
193. Schachter MB. Our treatment program for cancer. Schachter Center for Complementary Medicine. Available at: http://schachtercenter.com/ tx_cancer.htm Accessed March 7, 2008.
194. We are proud to announce that we are participating in the NanobacTX-ACES Research Trial. Schachter Center for Complementary Medicine. Available at: http://web.archive.org/web/20030215014728/http://www.mbschachter.com/ NanobacTX-ACES+Research+Trial.htm Accessed March 7, 2008.
195. The Talk about TACT. An interview with Dr. John Gannage. Healthy ways. Markham Integrative Medicine Newsletter. 2007;4(1). Available at: http://www3.sympatico.ca/gannage.markham/newsletters/ 2007_Newsletter_Winter.pdf Accessed March 7, 2008.
196. US Food and Drug Administration. Code of Federal Regulations. 21 CFR310.3. New drugs. Available at: http://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=310.3&SearchTerm=new%20drug Accessed March 7, 2008.
197. Physician group backs new NIH chelation therapy study for heart disease [press release]. Laguna Hills, Calif: American College for Advancement in Medicine; August 14, 2002. Available at: http://web.archive.org/web/ 20030626012903/http://www.acam.org/press_releases/20020814.php Accessed March 7, 2008.
198. Internet Archive Wayback Machine. Searched for: ClinicalTrials.gov. Trial to Assess Chelation Therapy (TACT). Available at: http://web.archive.org/web/*/http://www.clinicaltrials.gov/show/ NCT00044213 Accessed March 7, 2008.
199. Brecher A. ICIM update: International College of Integrative Medicine offers new agenda for discerning docs - formerly GLCCM - ICIM. Townsend Letter for Doctors and Patients, January 2003. Available at: http://www.findarticles.com/p/articles/mi_mOISW/is_2003_Jan/ai_95676487 Accessed March 7, 2008.
200. Citizens for Responsible Care and Research (CIRCARE). Trial to Assess Chelation Therapy (TACT): Table B: TACT Chelation Practitioner Principal Investigators With State Board Actions. Available at: http://www.circare.org/tact/tact_pidtable.htm Accessed May 2, 2008.
201. Citizens for Responsible Care and Research (CIRCARE). Trial to Assess Chelation Therapy (TACT): Table C: TACT Chelation Practitioner Principal Investigators With Criminal Convictions and Federal Civil Judgments. Available at: http://www.circare.org/tact/tact_pilegaitable.htm Accessed May 2, 2008.
202. USA v. Kraucak. Case No. 02CR00001 Docket sheet. United States District Court Middle District of Florida (Tampa). June 7, 2002. Available at: http:/www.circare.org/tact/02cr00001_docketsheet.pdf Accessed March 7, 2008.
203. State of Florida Board of Medicine v. Nelson Kraucak, M.D. Final Order. February 26, 2003. Available at: http://www.circare.org/tact/ kraucak_20030226.pdf Accessed March 7, 2008.
204. Citizens for Responsible Care and Research (CIRCARE). Trial to Assess Chelation Therapy (TACT): Table D: TACT Chelation Practitioner Principal Investigator Memberships. Available at: http://www.circare.org/tact/ tact_ccpmemberships.htm Accessed April 27, 2008.
205. In the United States District Court for the District of Nebraska. United States of America, Plaintiff, vs Richard Fleming, Defendant. 4:07CR 3005. Indictment (18 U.S.C. _st_st 1341, 1343, 1347, and 2). January 19, 2007. Available at: http://www.circare.org/lex/ 07cr3005_indictment_20070118.pdf Accessed April 27, 2008.
206. Mountainview Wellness Centre. Dr. Galina Bogatch, M.D. (UA), N.D. Available at: http://www.mountainview-wellness.ca/dr-galina-bogatch.php Accessed March 7, 2008.
207. Total Sensory Wellness Center. Who are we? Available at: http://www.totalsensorywellness.com/who.php#yo Accessed March 7, 2008.
208. Coyote Healing Center. Meet the doctor. Dr. David Rupley, Jr. Available at: http://coyotehealingcenter.com/ Accessed April 25, 2008.
209. Sherwood R. Doctor licensing under scrutiny. Critics seek audit of homeopathy board. The Arizona Republic. October 9, 2005. Available at: http://www.azcentral.com/arizonarepublic/news/articles/ 1009homeopathic09.html Accessed March 7, 2008.
210. Sherwood R. Homeopath patient's death debated despite Ariz. board clearing doctor. Complaint said infection allegedly stemmed from physician's treatment. The Arizona Republic. October 9, 2005. Available at: http://www.azcentral.com/arizonarepublic/news/articles/ 1009homeopathic09sidebar.html Accessed March 7, 2008.
211. FDA bioresearch monitoring information system for investigational new drug studies. October 18, 2007. Available at: http:/www.accessdata.fda.gov/scripts/cder/bmis/index.cfm Accessed March 7, 2008.
212. Lewis Mehl-Madrona biography and C.V. Available at: http://mehimadrona.mysite.com/index_2.html Accessed March 7, 2008.
213. US Food and Drug Administration. Code of Federal Regulations. Title 21, part 312. Investigational new drug application. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/ CFRSearch.cfm?CFRPart=312&showFR=1 Accessed March 7, 2008.
214. ClinicalTrials.gov. Trial to Assess Chelation Therapy (TACT). Record last reviewed March 2004. Available at: http://web.archive.org/web/ 20040607000839/http://www.clinicaltrials.gov/show/NCT00044213 Accessed March 7, 2008.
215. North Carolina Integrative Medical Society. History. Available at: http://www.ncims.com/History.html Accessed March 7, 2008.
216. Before the North Carolina Medical Board. In Re: Rashid Ali Buttar, D.O., Respondent. Notice of Charges and Allegations: Notice of Hearing. November 20, 2007. Available at: http://glsuite.ncmedboard.org/DataTier/ Documents/Repository/0/0/5/9/df8fd9ba-c3da-4f0f-9338-0291be76dd7e.pdf Accessed March 7, 2008.
217. North Carolina Integrative Medical Society, Steering committee. Available at: http://www.ncims.com/Steedng_Committee.html Accessed March 7, 2008.
218. American Board of Clinical Metal Toxicology. Board of directors. Available at: http://abcmt.org/ Accessed March 7, 2008.
219. Watson DE, Burton D. Nomination of Rashid Ali Buttar, DO, FAAPM, FACAM, FAAIM for the NIH Director's Pioneer Award. 2004. Available at: http://www.hyperbaricmedicalassociation.org/docs/ NIH_Directors_Buttar.pdf#search=%22buttar%22burton%22 Accessed March 7, 2008.
220. Wellness and Longevity Center of Louisiana. Chelation therapy. 2003. Available at: http://www.healthybloodhealthybody.com/ svc_ChelationTherapy.htm Accessed March 7, 2008.
221. Chris Hatlestad, MD. Available at: http://www.chrishatlestadmd.com/ Accessed March 7, 2008.
222. American College for Advancement in Medicine (ACAM). 2004. Committee members. Available at: http://web.archive.org/web/20040507131007/ http://www.acam.org/committee.htm Accessed April 25, 2008.
223. US Food and Drug Administration. Code of Federal Regulations. 21CFR312.7. Available at: http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?FR=312.7 Accessed March 7, 2008.
224. US Food and Drug Administration. Code of Federal Regulations. 21CFR312.34. Available at: http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?FR=312.34 Accessed March 7, 2008.
225. Parrish Medical Center. Semi-annual report. March 2006. Available at: http://titusville.com/Files/ Hospital%20Semi%20Annual%20Report%20Memo%2003-06.pdf Accessed March 7, 2008.
226. Office for Human Research Protections (OHRP) Database. Institutional Review Board Information. IRB00001790 - Sterling Institutional Review Board IRB #1. August 28, 2007. Available at: http://ohrp.cit.nih.gov/ search/irbdtl.asp?IRBID=1728 Accessed March 7, 2008.
227. Sterling Institutional Review Board. Available at: http://www.sterlingirb.com/index.php Accessed March 7, 2008.
228. Chappell T. A white paper on safety and choice in medicine prepared for the Great Lakes College of Clinical Medicine and the American Preventive Medical Association. Townsend Letter for Doctors and Patients 2000. Available at: http:/www.tidp.com/issue/l1_00/safety.htm Accessed March 7, 2008.
229. Hoffman R. Common medical blunders. Conscious Choice. 1995. Available at: http://www.consciouschoice.com/1995-98/cc000/hmd081.html Accessed March 7, 2008.
230. Gannage J. Heart health and metabolic syndrome. Markham Integrative Medicine. Available at: http://www3.sympatico.ca/gannage.markham/ articles/hearthealthmetabolic.html Accessed March 7, 2008.
231. Dayton Medical Center. Informed consent and release from liability [alternative and complementary medicine (CAM)]. Available at: http://www.daytonmedical.com/pdf/Informed_Consent.pdf Accessed March 7, 2008.
232. American Heart Association. 2002. Questions and answers about chelation therapy. Available at: http://www.americanheart.org/ presenter.jhtml?identifier=3000843 Accessed March 7, 2008.
233. Lamas GA. Consent form, Trial to Assess Chelation Therapy(TACT). Version 1. January 2003. Citizens for Responsible Care and Research (CIRCARE). Available at: http://www.circare.org/tact/tactconsentform_20030113.pdf Accessed March 7, 2008.
234. Null G, Seaman B. Detoxification therapies. Innerself.com. 2000. Available at: http://web.archive.org/web/20061205041649rn_1/ innerself.com/Health/detoxification.htm Accessed April 25, 2008.
235. Bell SA, Strassberg D, Knudtson ML. Chelation therapy for patients with ischemic heart disease. JAMA. 2002;287:2077-2078.
236. Kartikasari AER, Georgiou NA, Visseren FL, van Kats-Renaud H, van Asbeck BS, Marx JJ. Endothelial cell activation by EDTA chelation therapy. In: Kartikasari AER, ed. Iron Modulates Phagocyte-Endothelial Cell Interactions: Implications for Atherosclerosis [dissertation]. Utrecht, The Netherlands: Proefschrift Universiteit Utrecht; 2006. Available at: http://igitur-archive.library.uu.nl/dissertations/2006-0322-200123/ c6.pdf Accessed March 7, 2008.
237. Buettner GR, Jurkiewicz BA. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res. 1996;145:532-541.
238. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J. Vitamin C exhibits pro-oxidant properties. Nature. 1998;392:559.
239. Cook JD, Reddy MB. Effect of ascorbic acid intake onnonheme-iron absorption from a complete diet. Am J Clin Nutr. 2001;73:93-98.
240. Fleming DJ, Tucker KL, Jacques PF, Dallal GE, Wilson PW, Wood RJ. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr. 2002;76:1375-1384.
241. Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J. 1999;13:1007-1024.
242. Evans DA, Tariq M, Sujata B, McCann G, Sobki S. The effects of magnesium sulphate and EDTA in the hypercholesterolaemic rabbit. Diabetes Obes Metab. 2001;3:417-422.
243. O'Brien SF, Kelly SE, Dolphin PJ, Russell JC. Chelation therapy in the JCR:LA-cp rat: experimental assessment of a putative antiatherosclerotic treatment. Clin Invest Med. 2000;23:124-131.
244. Kaman RL, Rudolph CJ, McDonagh EW, Walker FM. Effect of EDTA chelation therapy on aortic calcium in rabbits on atherogenic diets: quantitative and histochemical studies. J Adv Med. 1990;3:13-22.
245. Clarke NE, Clarke CN, Mosher RE. The in vivo dissolution of metastatic calcium. An approach to atherosclerosis. Am J Med Sci. 1955;229:142-149.
246. Boyle AJ, Jasper JJ, McCormick H, et al. Studies in human and induced atherosclerosis employing EDTA. Bull Swiss Acad Med Sci. 1957;13:408.
247. Clarke NE Sr. Atherosclerosis, occlusive vascular disease and EDTA. Am J Cardiol. 1960;6:233-236.
248. Kitchell JR, Meltzer LE, Seven MJ. Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis. 1961;3:338-349.
249. Boyle AJ, Clarke NE, Mosher RE, McCann DS. Chelation therapy in circulatory and sclerosing diseases. Fed Proc. 1961;20(pt2):243-252.
250. Meltzer LE, Kitchell JR, Palmon F Jr. The long term use, side effects, and toxicity of disodium ethylenediamine tetraacetic acid (EDTA). Am J Med Sci. 1961;242:51-67.
251. Beecher HK. Surgery as placebo: a quantitative study of bias. JAMA. 1961;176:1102-1107.
252. Benson H, McCallie DP Jr. Angina pectoris and the placebo effect. N Engl J Med. 1979;300:1424-1429.
253. Edetate disodium injection USP. IND 11355 Panel on Cardiovascular Drugs. National Academy of Science - National Research Council. 1970. Available at: http://www.circare.org/foia2/ind_11355cardiovascular.pdf Accessed March 7, 2008.
254. Kitchell JR, Glover RP, Kyle RH. Bilateral internal mammary artery ligation for angina pectoris. Preliminary clinical considerations. Am J Cardiol. 1958;1:46-50.
255. Casdorph HR. EDTA chelation therapy, efficacy in arteriosclerotic disease. J Holistic Med. 1981;3:53-59.
256. Evers R. Chelation of vascular atheromatous disease. 1979. Available at: http://www.circare.org/tact/evers_3000cases.pdf Accessed March 7, 2008.
257. Lieberman P, Linn R. Deaths become issue in Evers' stay in Louisiana. Atlanta Journal-Constitution. December 18, 1978.
258. Rorison D. Louisiana State Board of Medical Examiners. Letter to Robert McKim Bell. June 6, 1993. Citizens for Responsible Care and Research (CIRCARE). Available at: http://www.circare.org/tact/ rorison_bell19930603.pdf Accessed March 7, 2008.
259. Alabama Board of Medical Examiners vs. Herbert Ray Evers, M.D. Complaint and petition for revocation of license. November 25, 1985. Available at: http://www.circare.org/pd/eversalcomplaint_19851125.pdf Accessed March 7, 2008.
260. Alabama Board of Medical Examiners vs. Herbert Ray Evers, M.D. Order. December 17, 1986. Available at: http://www.circare.org/pd/ eversalorder_19861217.pdf Accessed March 7, 2008.
261. Evers HR. Agreement between physician and patient Ra-Mar Clinic. Available at: http://www.circare.org/tact/evers_chelationagreement.pdf Accessed March 7, 2008.
262. Bienenfeld L, Frishman W, Glasser SP. The placebo effect in cardiovascular disease. Am Heart J. 1996;132:1207-1221. Abstract
263. Packer M. The placebo effect in heart failure. Am Heart J. 1990;120(pt2):1579-1582.
264. Casdorph HR, Walker M. Toxic Metal Syndrome: How Metal Poisonings Can Affect Your Brain. New York: Penguin Group (USA); 1995. Available at: http://books.google.com/books?id=7GJEveEcurMC&pg=RA1-PA388&lpg= RA1-PA388&dq=casdorph+hr&source=web&ots=_2dnYdptn-&sig= 87NyrrzujAIFIvu7_H8u5IXQEoM#PRA1-PR13,M1 Accessed March 7, 2008.
265. Casdorph HR. Real Miracles: Indisputable Evidence That God Heals. Gainesville, Fla: Bridge-Logos Publishers; 2003.
266. Caro JJ, Migliaccio-Walle K, Ishak KJ, Proskorovsky I. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord. 2005;5:14.
267. Connock M, Wilson J, Song F, et al. Chelation therapy for Intermittent Claudication and Coronary Heart Disease: A Birmingham Technology Assessment Group Report. Birmingham: West Midlands Health Technology Assessment Collaboration, Dept of Public Health and Epidemiology, University of Birmingham; 2002. Available at: http://rep.bham.ac.uk/pdfs/ 2002/chelation.pdf Accessed March 7, 2008.
268. Spence JD. Statement to the Assembly Health Committee of the California Legislature re: SB 1474 and 1475. 1976. Available at: http://www.circare.org/foia2/spence_statementSB1474_1976.pdf Accessed March 7, 2008.
269. Hancke C, Flytlie K. Benefits of EDTA chelation therapy in arteriosclerosis: a retrospective study of 470 patients. J Adv Med. 1993;6:161-171. Available at: http://www.detoxamin.com/studies/study1/ index.html Accessed March 7, 2008.
270. The Danish Committees on Scientific Dishonesty. Annual Report, 1993. Chapter 7, Case 5. Available at: http://web.archive.org/web/ 20010513004631/http://www.forsk.dk/eng/uvvu/publ/annreport93/chap7.htm Accessed March 7, 2008.
271. Lamb DJ, Leake DS. The effect of EDTA on the oxidation of low density lipoprotein. Atherosclerosis. 1992;94:35-42.
272. Hoekstra PP III, Gedye JL, Hoekstra P, et al. Serial infusions of magnesium disodium ethylene diamine tetraacetic acid enhance perfusion in human extremities. Pre-publication draft, Therma-Scan, Inc, 26711 Woodward Ave, Huntington Woods, MI 48070, 1993. Available at: http://www.etoxamin.com/studies/study6/index.html Accessed March 7, 2008.
273. Grier MT, Meyers DG. So much writing, so little science: a review of 37 years of literature on edentate sodium chelation therapy. Ann Pharmacother. 1993;27:1504-1509.
274. Cobb LA, Thomas GI, Dillard DH, Merendino KA, Bruce RA. An evaluation of internal-mammary-artery ligation by a double-blind technic. N Engl J Med. 1959;260:1115-1118.
275. Glover RP, Kitchell JR, Davila JC, Barkley HT Jr. Bilateral ligation of the internal mammary artery in the treatment of angina pectoris. Experimental and clinical results. Am J Cardiol. 1960;6:937-945.
276. Dimond EG, Kittle CF, Crockett JE. Comparison of internal mammary artery ligation and sham operation for angina pectoris. Am J Cardiol. 1960;5:483-486.
277. Fremont RE, Klopstock R, Glass P. Controlled studies on the efficacy of bilateral internal mammary artery ligation in patients with angina pectoris. Angiology. 1959;10:20-27.
278. Straus SE. Dancing with a dream: the folly of pursuing alternative medicine (in reply). Acad Med. 2001;76:303.
279. Moertel CG, Fleming TR, Rubin J, et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med. 1982;306:201-206.
280. Bross IDJ, Pauling L, Culbert ML. Laetrile. N Eng J Med. 1982;307:118-119.
281. Moertel CG. Laetrile. N Eng J Med. 1982;307:120.
282. Milazzo S, Ernst E, Lejeune S, Schmidt K. Laetrile treatment for cancer. Cochrane Database of Systematic Reviews. 2006;(2). Available at: http://www.cochrane.org/reviews/en/ab005476.html Accessed April 25, 2008.
283. Herbert V. Laetrile. N Engl J Med. 1982;307:119.
284. Greenberg DM. The case against laetrile: the fraudulent cancer remedy. Cancer. 1980;45:799-807.
285. Andrews RC. Laetrile. N Eng J Med. 1982;307:119.
286. Cassileth BR. Sounding boards. After Laetrile, what? N Engl J Med. 1982;306:1482-1484.
287. Lewis C. Online Laetrile vendor ordered to shut down. Quackwatch. November 28, 2003. Available at: http://www.quackwatch.org/ 02ConsumerProtection/FDAActions/vale.html Accessed March 7, 2008.
288. US Food and Drug Administration. FDA takes action against firms marketing unapproved drugs. FDA Talk paper, T00-39, September 6, 2000. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS01032.html Accessed March 7, 2008.
289. Findings and Order of the Ohio State Medical Board in the Matter of Jack E. Slingluff D.O. November 10, 2004. Available at: http://www.bioethicswatch.org/foia/34001265.pdf Accessed March 7, 2008.
290. Freedenfeld SH. Introduction to CAM therapies for cancer. Stockton Family Practice. Available at: http://www.stocktonfp.com/Articles/ CancerIntroduction.pdf Accessed March 7, 2008.
291. Foreman H. Toxic side effects of ethylenediaminetetraacetic acid. J Chron Dis. 1963;16:319.
292. Perry HM, Schroeder HA. Lesions resembling B complex deficiency and urinary loss of zinc produced by ethylene diamine tetra-acetate. Am J Med. 1957;22:168-172.
293. Meltzer LE, Palmon F Jr, Kitchell JR. Hypoglycemia induced by disodium ethylenediamine tetra-acetic acid. Lancet. 1961;2:637-638.
294. Chelation Centers. Available at: http://www.chelationcenters.com/ Accessed March 7, 2008.
295. American Board of Clinical Metal Toxicology. Find a Physician. Florida. Available at: http://abcmt.org/ Accessed April 25, 2008.
296. American College for Advancement in Medicine (ACAM). Find an ACAM physician. Neil Ahner, MD. Available at: http://www.acam.org/dr_search/ index.php?q=Ahner&field=lname&submitted=1 Accessed March 7, 2008.
297. American Academy of Medical Preventics. Listing of 1986-1987 officers and directors.
298. American College for Advancement in Medicine (ACAM). Find an ACAM physician. Roy Kerry, MD. Available at: http://www.acam.org/dr_search/ index.php?q=Kerry&field=lname&submitted=1 Accessed March 7, 2008.
299. Testimony of Roy E. Kerry. In: Board of Medical Examiners of the State of Iowa. In the matter of the complaint and statement of charges against V. Thomas Riley, MD. March 20, 1998. Available at: http://www.docboard.orglia/legat/ Riley,V.Thomas,M.D.-02-1991-104,02-1991-229,02-1993-197.PDF Accessed March 7, 2008.
300. American College for Advancement in Medicine (ACAM). Find an ACAM physician. Donald McBride, ND. Available at: http://www.acam.org/ dr_search/index.php?q=McBride&search=Search&field= lname&submitted=1 Accessed March 7, 2008.
301. State of Connecticut Department of Public Health Bureau of Healthcare Systems. In Re: Robban Sica, M.D. Petition No. 2002-0306-001-043. Statement of Charges. 2003. In: Barrett S. Regulatory actions against Robban Sica, M.D. Revised February 2005. Quackwatch. Available at: http://www.quackwatch.org/11Ind/sica.html Accessed March 7, 2008.
302. Casewatch. Settlement agreement with Robban Sica, M.D. (2005). Available at: http://www.casewatch.org/board/med/sica/seftlement.shtml Accessed March 7, 2008.
303. Morgan BW, Singleton K, Thomas JD. Adverse effects in 5 patients receiving EDTA at an outpatient chelation clinic. Vet Hum Toxicol. 2002;45:274-276.
304. Soffer A, Toribara T, Moore-Jones D, Weber D. Clinical applications and untoward reactions of chelation in cardiac arrhythmias. Arch Intern Med. 1960;106:824-834.
305. Bleys J, Miller ER III, Pastor-Barriuso R, Appel LJ, Guallar E. Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2006;84:880-887.
306. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;37-46.
307. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842-857.
308. Melhus H, Michaelsson K, Kindmark A, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med. 1998;129:770-778.
309. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA. 2002;287:47-54.
310. Cranton EM, ed. A Textbook on EDTA Chelation Therapy. 2nd ed. Charlottesville, Va: Hampton Roads Publishing; 2001.
311. International College of Integrative Medicine. Board members. Available at: http://icimed.com/board2007.php Accessed March 7, 2008.
312. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest. 1986;77:757-761.
313. Maxwell SR. Antioxidant vitamin supplements: update of their potential benefits and possible risks. Drug Saf. 1999;21:253-266.
314. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432-2440.
315. Gifford F. So-called "clinical equipoise" and the argument from
316. Miller FG, Brody H. Clinical equipoise and the incoherence of research ethics. J Med Philos. 2007;32:151-165.
317. Veatch RM. The irrelevance of equipoise. J Med Philos. 2007;32:167-183.
318. Miller PB, Weijer C. Equipoise and the duty of care in clinical research: a philosophical response to our critics. J Med Philos. 2007;32:117-133.
319. Beyerstein BL. Social and judgmental biases that make inert treatments seem to work. Sci Rev Alt Med. 1999;3:33. Available at: http://www.sram.org/0302/bias.html Accessed March 7, 2008.
320. Cranton EM, Frackelton JP. Current status of EDTA chelationtherapy in occlusive arterial disease. J Hol Med. 1982;4:24-33. Available at: http://www.detoxamin.com/studies/studyl8/index.html Accessed April 25, 2008.
321. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Advance data from vital and health statistics: no 343. Hyattsville, Md: National Center for Health Statistics; 2004. Available at: http://www.cdc.gov/ nchs/data/ad/ad343.pdf Accessed March 7, 2008.
322. Stalker OF. Evidence and alternative medicine. Mt Sinai J Med. 1995;62:132-143.
323. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med. 1999;130:995-1004. Available at: http://www.annals.org/cgi/content/full/130/12/995 Accessed March 7, 2008.
324. Goodman SN. Toward evidence-based medical statistics. 2: The Bayesfactor. Ann Intern Med. 1999;130:1005-1013. Available at: http://www.annals.org/cgi/content/full/130/12/1005 Accessed March 7, 2008.
325. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals. February 2006. Available at: http://www.icmje.org/ Accessed March 7, 2008.
326. International Committee of Medical Journal Editors. Journals that have requested inclusion on the list of publications that follow the ICMJE's Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Available at: http://www.icmje.org/jmlist.html Accessed March 7, 2008.